Innoviva, Inc. - Common Stock (NQ:INVA)

20.50 -0.05 (-0.24%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024 ↗

July 09, 2024

A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.

Via InvestorPlace

3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge ↗

June 27, 2024

Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries.

Via InvestorPlace

Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs ↗

June 18, 2024

Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.

Via Benzinga

Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

June 03, 2024

From Innoviva, Inc.

Via Business Wire

3 Under-$20 Stocks That Could Make You a Fortune ↗

May 31, 2024

Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries.

Via InvestorPlace

A Look Into Healthcare Sector Value Stocks ↗

May 15, 2023

Via Benzinga

5 Value Stocks In The Healthcare Sector ↗

May 08, 2023

Via Benzinga

INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024 ↗

May 08, 2024

INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress

May 08, 2024

From Innoviva, Inc.

Via Business Wire

Innoviva to Participate in the BofA Securities Health Care Conference

May 08, 2024

From Innoviva, Inc.

Via Business Wire

Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024

April 24, 2024

From Innoviva Specialty Therapeutics

Via Business Wire

5 Value Stocks In The Healthcare Sector ↗

March 04, 2024

Via Benzinga

Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress

February 29, 2024

From Innoviva, Inc.

Via Business Wire

If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names ↗

January 10, 2024

Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.

Via InvestorPlace

Chart Of The Day: Innoviva - Individual Investor Favorite ↗

January 08, 2024

100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha

Via Talk Markets

Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 01, 2023

From Innoviva, Inc.

Via Business Wire

Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea

November 01, 2023

From Innoviva Specialty Therapeutics

Via Business Wire

A Look Into Healthcare Sector Value Stocks ↗

October 02, 2023

Via Benzinga

Innoviva to Participate in the Cantor Global Healthcare Conference

September 19, 2023

From Innoviva, Inc.

Via Business Wire

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

September 18, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Appoints Stephen Basso as Chief Financial Officer

August 25, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 02, 2023

From Innoviva, Inc.

Via Business Wire

Overview Of Value Stocks In The Healthcare Sector ↗

July 31, 2023

Via Benzinga

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now ↗

July 11, 2023

With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.

Via InvestorPlace

Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference

June 06, 2023

From Innoviva, Inc.

Via Business Wire

AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter ↗

May 24, 2023

Via Benzinga

Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use

May 23, 2023

From Innoviva, Inc.

Via Business Wire

Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying ↗

May 16, 2023

Although US stocks closed higher on Monday, there were a few notable insider trades.

Via Benzinga

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

May 11, 2023

From Innoviva, Inc.

Via Business Wire

Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 09, 2023

From Innoviva, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.